Cancer Immune Therapy Edited by G. Stuhler and P. Walden ...

lymphocytes in a human melanoma.
Science 1995; 269: 1281±4.
57 Robbins PF, El-Gamil M, Li YF, Kawakami
Y, Loftus D, Appella E, Rosenberg
SA. A mutated b-catenin gene encodes
a melanoma-specific antigen recognized
by tumor infiltrating lymphocytes.
J Exp Med 1996; 183: 1185±92.
58 Feltkamp MC, Smits HL, Vierboom
MP, Minnaar RP, de Jongh BM,
Drijfhout JW, ter Schegget J, Melief
CJ, Kast WM. Vaccination with cytotoxic
T lymphocyte epitope-containing
peptide protects against a tumor induced
by human papillomavirus type
16-transformed cells. Eur J Immunol
1993; 23: 2242±9.
59 Ressing ME, Sette A, Brandt RM,
Ruppert J,Wentworth PA, Hartman
M, Oseroff C, Grey HM,
Melief CJ, Kast WM. Human CTL epitopes
encoded by human papillomavirus
type 16 E6 and E7 identified
through in vivo and in vitro immunogenicity
studies of HLA-A*0201-binding
peptides. J Immunol 1995; 54: 5934±43.
60 Ellis JR, Keating PJ, Baird J, Hounsell
EF, Renouf DV, Rowe M, Hopkins
D, Duggan-Keen MF, Bartholomew
JS,Young LS, Stern PL. The association
of an HPV16 oncogene variant
with HLA-B7 has implications for vaccine
design in cervical cancer. Nat Med
1995; 1: 464±70.
61 Rosenberg SA,White DE. Vitiligo in
patients with melanoma: normal tissue
antigens can be targets for cancer immunotherapy.
J Immunother Emphasis
Tumor Immunol 1996; 19: 81±4.
62 Kawakami Y, Eliyahu S, Jennings C,
Sakaguchi K, Kang X, Southwood S,
Robbins PF, Sette A, Appella E, Rosenberg
SA. Recognition of multiple epitopes
in the human melanoma antigen
gp100 by tumor-infiltrating T lymphocytes
associated with in vivo tumor regression.
JImmunol1995; 154: 3961±8.
63 Kawakami Y, Robbins PF,Wang X,
Tupesis JP, Parkhurst MR, Kang X,
Sakaguchi K, Appella E, Rosenberg
SA. Identification of new melanoma
epitopes on melanosomal proteins
recognized by tumor infiltrating
T lymphocytes restricted by HLA-A1,
References
-A2, and -A3 alleles. J Immunol 1998;
161: 6985±92.
64 Panelli MC, Bettinotti MP, Lally K,
Ohnmacht GA, Li Y, Robbins P,
Riker A, Rosenberg SA, Marincola
FM. A tumor-infiltrating lymphocyte
from a melanoma metastasis with
decreased expression of melanoma differentiation
antigens recognizes
MAGE-12. J Immunol 2000; 164: 4382±
92.
65 Becker JC, Guldberg P, Zeuthen J,
Brocker EB, Straten PT. Accumulation
of identical T cells in melanoma
and vitiligo-like leukoderma. J Invest
Dermatol 1999; 113: 1033±8.
66 Dudley ME, Roopenian DC. Loss of a
unique tumor antigen by cytotoxic T
lymphocyte immunoselection from a
3-methylcholanthrene-induced mouse
sarcoma reveals secondary unique and
shared antigens. J Exp Med 1996; 184:
441±7.
67 Jager E, Chen YT, Drijfhout JW, Karbach
J, Ringhoffer M, Jager D,
Arand M,Wada H, Noguchi Y, Stockert
E, Old LJ, Knuth A. Simultaneous
humoral and cellular immune response
against cancer-testis antigen NY-ESO-1:
definition of human histocompatibility
leukocyte antigen (HLA)-A2-binding
peptide epitopes. J Exp Med 1998; 187:
265±70.
68 Chaux P,Vantomme V, Stroobant V,
Thielemans K, Corthals J, Luiten R,
Eggermont AM, Boon T, van der
Bruggen P. Identification of MAGE-3
epitopes presented by HLA-DR molecules
to CD4 + T lymphocytes. J Exp
Med 1999; 189: 767±78.
69 Jager E, Jager D, Karbach J, Chen YT,
Ritter G, Nagata Y, Gnjatic S, Stockert
E, Arand M, Old LJ, Knuth A.
Identification of NY-ESO-1 epitopes
presented by human histocompatibility
antigen (HLA)-DRB4*0101±0103 and
recognized by CD4 + T lymphocytes of
patients with NY-ESO-1-expressing melanoma.
J Exp Med 2000; 191: 625±30.
70 Dietrich PY,Walker PR, Quiquerez
AL, Perrin G, Dutoit V, Lienard D,
Guillaume P, Cerottini JC, Romero P,
Valmori D. Melanoma patients respond
to a cytotoxic T lymphocyte-defined self-
245